| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
FORT LAUDERDALE, Fla.—A global provider of drug development and commercialization solutions and services has signed a new agreement extending its relationship with OmniComm Systems Inc., a provider of clinical data management technology, for another seven years. Under the terms of the agreement, the contract research organization (CRO) will use OmniComm’s TrialOne eClinical solution to automate early-phase studies at one of its U.S.-based clinical research units.
 
The CRO selected TrialOne, apart from its status as the market-leading eSource and site automation system for Phase 1 clinics, because TrialOne enables research organizations to greatly improve the productivity and efficiency of their Phase 1 clinics.
 
Browser-based, tablet-compatible TrialOne streamlines and automates key processes for early-phase clinics, which drive efficiencies and reduce timelines and costs through faster and more directed volunteer recruitment, easy-to-build schedule-based workflows, real-time bedside data collection, direct data capture from devices, sample processing automation and data processing. The automation reduces workload on clinic staff and improves the clinical trial experience for volunteers.
 
“Each new contract documents TrialOne’s position as the market-leading eSource solution for Phase 1 clinics,” said Dr. Kuno van der Post, OmniComm’s chief commercial officer. “We’re excited to continue building our partnership with this leading CRO.”

Related Topics

Published In

Volume 14 - Issue 11 | November 2018

November 2018

November 2018 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A 3D illustration of two DNA strands in a transparent bubble

Overcoming barriers in gene therapy 

Advanced gene editing, delivery, and analytical tools are driving better gene therapies.
An illustration of the human brain

A multiomic approach to profiling brain tumors

Probing the molecular drivers of brain metastasis reveals novel therapeutic targets.
A 3D illustration of purple-colored cancer cells surrounded by transparent immune cells with yellow nuclei

Enhancing immune cell profiling with digital technologies 

Software innovations help researchers decode immune complexity in cancer.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue